ClinicalTrials.gg
RecruitingNCT07175220Updated Nov 18, 2025

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

A Phase 2 interventional study of SHR2554; SHR-A2102 and SHR2554; Adabelimumab in Locally Advanced or Metastatic Non-small Cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd. — 18 open to participants now, 22 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
22nd of 38
200 · median 274
Started
2025
with 4 others
Phase 2
14 of 38
5 open now
Primary completion
2028-10
later than 15 of 21 live
Registered
30th of 38
by date

Among the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd., this one is the 22nd largest by planned enrollment, is one of 5 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 15 of the 21 other live ones, and was the 30th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer

03

Conditions studied

  • Locally Advanced or Metastatic Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range of 18-75 years old (including both ends), gender not limited;
  2. Patients with locally advanced unresectable or non-small cell lung cancer diagnosed by pathology
  3. score is 0 or 1
  4. Expected survival period ≥ 12 weeks
  5. Has a good level of organ function
  6. Patients voluntarily joined the study and signed

Exclusion criteria

Exclusion Criteria:

  1. Having difficulty swallowing or malabsorption syndrome or any other uncontrolled gastrointestinal disease (such as nausea, diarrhea, or vomiting), having undergone gastrectomy or gastric banding surgery, etc
  2. Symptomatic or active central nervous system tumor
  3. Previously or simultaneously suffering from other malignant tumors
  4. Spinal cord compression that cannot be cured by surgery and/or radiotherapy
  5. Accompanied by uncontrolled tumor related pain
  6. Plan to receive any other anti-tumor treatment during this trial period
  7. Receive other anti-tumor treatments within 4 weeks before the first medication
  8. Having undergone major surgeries other than diagnosis or within 28 days prior to the first administration
  9. Currently participating in other clinical studies or taking medication for the first time less than 4 weeks after the end of the previous clinical study
  10. Moderate to severe pleural effusion with clinical symptoms
  11. Individuals with active pulmonary tuberculosis infection within one year prior to the first use of medication
  12. Subjects who have experienced severe infections within 30 days prior to their first medication use
  13. Administer attenuated within 30 days before the first use of medication.
  14. History of immunodeficiency
  15. Suffering from poorly controlled or severe cardiovascular and cerebrovascular diseases
  16. History of interstitial pneumonia/non infectious pneumonia requiring hormone therapy in the past
  17. AE caused by previous anti-tumor treatment has not recovered to v5.0 level evaluation ≤ 1
  18. Untreated active hepatitis
  19. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  20. There are other serious physical or mental illnesses or laboratory abnormalities present
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Queue A

    Drug: SHR2554; SHR-A2102

  • Experimental
    Queue B

    Drug: SHR2554; Adabelimumab

  • Experimental
    Queue C

    Drug: SHR2554; SHR-1701

Interventions

06

What researchers measure

Primary outcomes

  1. DLT

    Time frame: 21days after the first administration of each subject

  2. AE

    Time frame: from Day1 to 30 days after last dose

  3. Incidence and severity of serious adverse events (SAE)

    Time frame: from Day1 to 30 days after last dose

  4. ORR

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

Secondary outcomes

  1. Immunogenic indicators: anti-SHR-A2102 antibody (ADA)

    Time frame: through study completion, an average of 2 years

  2. Duration of response (DoR)

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

  3. disease control rate (DCR)

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

  4. progression free survival (PFS)

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

  5. overall survival (OS)

    Time frame: from first dose to disease progression or death, whichever comes first, up to 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 36 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 16, 2025
StartActual
Oct 9, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07175220
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Oct 9, 2025
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 18, 2025

Study contacts

Xiaoxue Pi
Contact
Xiaoxue.pi@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zeprumetostat · Notiretatug rezetecan · SHR-1701

Start the discussion